Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models

References

• Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893–917.
   PubMed Web of Science ®Google Scholar
• Cassell A, Grandis JR. Investigational EGFR-targeted therapies in HNSCC. Expert Opin Investig Drugs 2010; 19:709–22.
   PubMed Web of Science ®Google Scholar
• Ang KK, Berkey BA, Tu X, Zhang H-Z, Katz R, Hammond EH, Fu KK, Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62:7350–6.
   PubMed Web of Science ®Google Scholar
• Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013; 19:1389–400.
   PubMed Web of Science ®Google Scholar
• Aung KL, Siu LL. Genomically personalized therapy in head and neck cancer. Cancers Head Neck 2016; 1:2.
   Google Scholar
• Mologni L. Inhibitors of the anaplastic lymphoma kinase. Expert Opin Investig Drugs 2012; 21:985–94.
   PubMed Web of Science ®Google Scholar
• Blackhall F, Cappuzzo F. Crizotinib: from discovery to accelerated development to front-line treatment. Ann Oncol Off J Eur Soc Med Oncol 2016; 27 Suppl 3:iii35–iii41.
   PubMedGoogle Scholar
• Shaw AT, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370:2537–9.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov 2012; 2:401–4.
   PubMed Web of Science ®Google Scholar
• Huang T-T, Gonzales CB, Gu F, Hsu Y-T, Jadhav RR, Wang C-M, Redding SW, Tseng C-E, Lee C-C, Thompson IM, et al. Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas. Carcinogenesis 2013; 34:1717–27.
   PubMed Web of Science ®Google Scholar
• Gonzales CB, De La Chapa JJ, Saikumar P, Singha PK, Dybdal-Hargreaves NF, Chavez J, Horning AM, Parra J, Kirma NB. Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma. Oral Oncol 2016; 59:12–9.
   PubMed Web of Science ®Google Scholar
• Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci 2007; 104:270–5.
   PubMed Web of Science ®Google Scholar
• Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res 2013; 73:285–96.
   PubMed Web of Science ®Google Scholar
• Blucher AS, Choonoo G, Kulesz-Martin M, Wu G, McWeeney SK. Evidence-Based Precision Oncology with the Cancer Targetome. Trends Pharmacol Sci 2017;
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517:576–82.
   PubMed Web of Science ®Google Scholar
• Kondo N, Ishiguro Y, Kimura M, Sano D, Fujita K, Sakakibara A, Taguchi T, Toth G, Matsuda H, Tsukuda M. Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. Oncol Rep 2008; 20:373–8.
   PubMed Web of Science ®Google Scholar
• Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Sol Degese M, Vitale-Cross L, Chen Q, Gutkind JS. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst 2014; 106.
   Google Scholar
• De Felice F, Guerrero Urbano T. New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors. Oral Oncol 2017; 67:119–23.
   PubMed Web of Science ®Google Scholar
• Jimeno A, Shirai K, Choi M, Laskin J, Kochenderfer M, Spira A, Cline-Burkhardt V, Winquist E, Hausman D, Walker L, et al. A randomized, phase 2 trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase Inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Ann Oncol 2014;:mdu574.
   Google Scholar
• Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013; 56:5675–90.
   PubMed Web of Science ®Google Scholar
• Huang W-S, Liu S, Zou D, Thomas M, Wang Y, Zhou T, Romero J, Kohlmann A, Li F, Qi J, et al. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. J Med Chem 2016; 59:4948–64.
   PubMed Web of Science ®Google Scholar
• Uchibori K, Inase N, Araki M, Kamada M, Sato S, Okuno Y, Fujita N, Katayama R. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun 2017; 8:14768.
   PubMed Web of Science ®Google Scholar
• Chou T-C. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Res 2010; 70:440–6.
   PubMed Web of Science ®Google Scholar
• Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 2014; 42:D1091–1097.
   PubMed Web of Science ®Google Scholar
• Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, et al. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U A 2009; 106:8695–700.
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Korenchuk S, Rowand JL, Groy A, Liu Q, Leperi D, Atkins C, Dumble M, Yang J, Anderson K, et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther 2009; 8:2811–20.
   PubMed Web of Science ®Google Scholar
• Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci 2011; 108:7535–40.
   PubMed Web of Science ®Google Scholar
• Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, O'Hare T, Druker BJ. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 2015; 112:E5381–90.
   PubMed Web of Science ®Google Scholar
• Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B, Yamamoto T. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997; 14:439–49.
   PubMed Web of Science ®Google Scholar
• Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, Witte DP. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997; 14:2175–88.
   PubMed Web of Science ®Google Scholar
• Moog-Lutz C, Degoutin J, Gouzi JY, Frobert Y, Brunet-de Carvalho N, Bureau J, Créminon C, Vigny M. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 2005; 280:26039–48.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, De Pas T, Besse B, Solomon BJ, Blackhall F, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385–94.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou S-HI, Dezube BJ, Jänne PA, Costa DB, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693–703.
   PubMed Web of Science ®Google Scholar
• Passoni L, Longo L, Collini P, Coluccia AML, Bozzi F, Podda M, Gregorio A, Gambini C, Garaventa A, Pistoia V, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 2009; 69:7338–46.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010; 28:1248–50.
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors—impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7:493–507.
   PubMed Web of Science ®Google Scholar
• Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K. Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells. Clin Cancer Res 2006; 12:4103–11.
   PubMed Web of Science ®Google Scholar
• Hoellein A, Pickhard A, von Keitz F, Schoeffmann S, Piontek G, Rudelius M, Baumgart A, Wagenpfeil S, Peschel C, Dechow T, et al. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget 2011; 2:599–609.
   PubMed Web of Science ®Google Scholar
• Jameson MJ, Beckler AD, Taniguchi LE, Allak A, VanWagner LB, Lee NG, Thomsen WC, Hubbard MA, Thomas CY. Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells. Mol Cancer Ther 2011; 10:2124–34.
   PubMed Web of Science ®Google Scholar
• Hanada N, Lo H-W, Day C-P, Pan Y, Nakajima Y, Hung M-C. Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog 2006; 45:10–7.
   PubMed Web of Science ®Google Scholar
• Hung L-Y, Tseng JT, Lee Y-C, Xia W, Wang Y-N, Wu M-L, Chuang Y-H, Lai C-H, Chang W-C. Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res 2008; 36:4337–51.
   PubMed Web of Science ®Google Scholar
• Jaganathan S, Yue P, Paladino DC, Bogdanovic J, Huo Q, Turkson J. A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PloS One 2011; 6:e19605.
   PubMed Web of Science ®Google Scholar
• Lo H-W, Hsu S-C, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih J-Y, Hung M-C. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005; 7:575–89.
   PubMed Web of Science ®Google Scholar
• Lo H-W, Cao X, Zhu H, Ali-Osman F. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol Cancer Res MCR 2010; 8:232–45.
   PubMed Web of Science ®Google Scholar
• Liao H-J, Carpenter G. Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res 2009; 69:6179–83.
   PubMed Web of Science ®Google Scholar
• Tan X, Lambert PF, Rapraeger AC, Anderson RA. Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications. Trends Cell Biol 2016; 26:352–66.
   PubMed Web of Science ®Google Scholar
• Huang W-C, Chen Y-J, Li L-Y, Wei Y-L, Hsu S-C, Tsai S-L, Chiu P-C, Huang W-P, Wang Y-N, Chen C-H, et al. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J Biol Chem 2011; 286:20558–68.
   PubMed Web of Science ®Google Scholar
• Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009; 28:3801–13.
   PubMed Web of Science ®Google Scholar
• Moog-Lutz C, Degoutin J, Gouzi JY, Frobert Y, Carvalho NB, Bureau J, Créminon C, Vigny M. Activation and Inhibition of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase by Monoclonal Antibodies and Absence of Agonist Activity of Pleiotrophin [Internet]. [cited 2017 May 31]; Available from: http://www.jbc.org
   Google Scholar
• Duijkers FAM, Gaal J, Meijerink JPP, Admiraal P, Pieters R, de Krijger RR, van Noesel MM. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels. Cell Oncol Dordr 2011; 34:409–17.
   PubMed Web of Science ®Google Scholar
• Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994; 73:187–90.
   PubMed Web of Science ®Google Scholar
• Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors: Similarities and differences. Crit Rev Oncol Hematol 2007; 62:53–61.
   PubMed Web of Science ®Google Scholar
• Rheinwald JG, O'connell TM. Intermediate Filament Proteins as Distinguishing Markers of Cell Type and Differentiated State in Cultured Human Urinary Tract Epithelia. Ann N Y Acad Sci 1985; 455:259–267.
   PubMed Web of Science ®Google Scholar
• Mesosecrin: a secreted glycoprotein produced in abundance by human mesothelial, endothelial, and kidney epithelial cells in culture. J Cell Biol 1987; 104:263–75.
   PubMed Web of Science ®Google Scholar
• Kulesz-Martin MF, McLimans WF. Steady-state cultures of human skin. Exp Cell Biol 1982; 50:195–206.
   PubMedGoogle Scholar
• Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 2012; 9:676–82.
   PubMed Web of Science ®Google Scholar
• Foty R. A simple hanging drop cell culture protocol for generation of 3D spheroids. J Vis Exp JoVE 2011;
   Web of Science ®Google Scholar
• Weiswald L-B, Guinebretière J-M, Richon S, Bellet D, Saubaméa B, Dangles-Marie V. In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy. BMC Cancer 2010; 10:106.
   PubMed Web of Science ®Google Scholar
• Cooper MR, Chim H, Chan H, Durand C. Ceritinib: A New Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer. Ann Pharmacother 2015; 49:107–12.
   PubMed Web of Science ®Google Scholar
• Khozin S, Blumenthal GM, Zhang L, Tang S, Brower M, Fox E, Helms W, Leong R, Song P, Pan Y, et al. FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer. Clin Cancer Res 2015; 21:2436–9.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. The Oncologist 2003; 8:303–6.
   PubMed Web of Science ®Google Scholar
• Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Müller S, Klebl B, Cotten M, Kéri G, et al. Cellular Targets of Gefitinib. Cancer Res 2005; 65:379–82.
   PubMed Web of Science ®Google Scholar
• McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F, et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 2005; 4:641–9.
   PubMed Web of Science ®Google Scholar
• Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD 1839 (Iressa): An Orally Active Inhibitor of Epidermal Growth Factor Signaling with Potential for Cancer Therapy. Cancer Res 2002; 62:5749–54.
   Google Scholar